Prediction and significance of synergy between antibiotics used for treatment for gram-negative sepsis
- PMID: 7399713
- DOI: 10.1007/BF01644935
Prediction and significance of synergy between antibiotics used for treatment for gram-negative sepsis
Abstract
Clinical tests capable of predicting synergism between penicillins and aminoglycosides are discussed. The results obtained in these tests are correlated to those of in vitro tests. Lack of in vitro synergism was associated with very low bactericidal activity in the serum. In order to determine the serum cidal activity tube dilutions were carried out using serum of plasma obtained from a patient who had received the antibiotic or a combination of drugs at a specified time before venipuncture. Dilutions were made with a pool of plasma or serum. This method needs further standardisation. It has been shown that the bactericidal dilutions of sera in patients treated with synergistic combinations were usually adequate, i. e. sera were active at a 1:8 dilution, while sera of most patients who received non-synergistic combinations were not active at this dilution. The determination of the bactericidal activity of the serum is not only a useful tool for monitoring therapy, it can be used also as an investigational means for comparing the respective efficacy of antibiotics administered alone or in combination. The test is probably more meaningful clinically than the simple in vitro microbiological studies or the determination of blood levels. It integrates some pharmacological characteristics of the drugs studied and the sensitivity of the pathogen to these drugs.
Similar articles
-
Serum bactericidal activity as a therapeutic guide in severely granulocytopenic patients with gram-negative septicemia.Eur J Cancer Clin Oncol. 1985 Apr;21(4):439-45. doi: 10.1016/0277-5379(85)90034-3. Eur J Cancer Clin Oncol. 1985. PMID: 3891360
-
The bactericidal activity in serum and its prognostic clinical value.Infection. 1983;11 Suppl 2:S93-6. doi: 10.1007/BF01645296. Infection. 1983. PMID: 6368398 Clinical Trial.
-
Combination therapy and monotherapy in the treatment of severe infection in the immunocompromised host.Am J Med. 1986 Jun 30;80(6B):149-55. doi: 10.1016/0002-9343(86)90493-6. Am J Med. 1986. PMID: 3728525
-
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.Am J Med. 1986 Jun 30;80(6B):126-37. doi: 10.1016/0002-9343(86)90490-0. Am J Med. 1986. PMID: 3088998 Review.
-
Antibiotic use in neonatal sepsis.Turk J Pediatr. 1998 Jan-Mar;40(1):17-33. Turk J Pediatr. 1998. PMID: 9722468 Review.
Cited by
-
In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.Antimicrob Agents Chemother. 1984 Apr;25(4):534-6. doi: 10.1128/AAC.25.4.534. Antimicrob Agents Chemother. 1984. PMID: 6428310 Free PMC article.
-
Combination therapy for treatment of infections with gram-negative bacteria.Clin Microbiol Rev. 2012 Jul;25(3):450-70. doi: 10.1128/CMR.05041-11. Clin Microbiol Rev. 2012. PMID: 22763634 Free PMC article. Review.
-
Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.Antimicrob Agents Chemother. 1982 Nov;22(5):743-52. doi: 10.1128/AAC.22.5.743. Antimicrob Agents Chemother. 1982. PMID: 7181485 Free PMC article.
-
Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.Folia Microbiol (Praha). 2009 Sep;54(5):391-4. doi: 10.1007/s12223-009-0054-1. Epub 2009 Nov 24. Folia Microbiol (Praha). 2009. PMID: 19937210
References
MeSH terms
Substances
LinkOut - more resources
Medical